Member Info for DeBull

Unfortunately it is very rare that PYC can publish the holy trinity of Contract length, Contract value and name associated with contract. We ar lucky to get 2 out of the 3, yesterday we got 1.

Do we like this, NO, but what the hell can we do. Nothing.

I agree that the way PS presents himself on the IMC etc does not look professional, its probably a workspace at Bee house.

It could be any that are listed as being in phase 1/2

Note our old friend BT1718 is in there. It has been completed https://delta.larvol.com/Products/?ProductId=f6f6030d-10f5-4d33-bb87-93baca5e4ad0 however, a new designation is on the CRUK website?

Https://www.cancerresearchuk.org/sites/default/files/cdd_pipeline_sept_2024.pdf

neatly shows where these targets are going through the trail phase.

Also notes that "There are 5 other undisclosed programmes in development: 2 small molecules, 2 antibodies and a peptide" So PYC work could be within these undisclosed 5?"

The drug target they could be working on could be in here:

https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-strategy-and-portfolio#portfolio1

Look at the Partnerships that are with CRUK on these targets.

Also, note in the PYC Bio at top of the RNS, now using the words "data science and biostatistics company"

Thank you Trench. So as i thought they addressed that question nearly a year ago, and made no replies since.

A very plausible argument Laura.

I think Ant was fighting fires over on ADVFN for years before posting here?

Trench, i read your post at 10.15. I have been the most vocal on the complete lack of the BOD buying at these levels. You mentioned that "on a recent IMC session" this question was asked. which one would that be Trench? I have listened back twice to the last Q&A part, and they did not mention it? They were asked this question in many guises, and did not reply to any of the "BOD Buying" questions i put to them.

I do not want to get on the wrong side of anyone, and i am sure Ant can fight his own battles, but i do think we ought to heed some of what he says? He was a founder after all.

Yes Trench, that is the way i see it to.

Ghebre and Mistry seem to be in charge of Biostats now?

Head of modelling & simulation has been appointed, just await the official announcement.

Mod & sim scientist job vacancy to be filled.

If Carlsberg did fund raises! Can only dream of that sort of fund raise here, with the backing they had.

PYC branching out into other diseases and illnesses can only be a good thing, as long as they do not spread themselves thinly on the projects they are working on.

True, thou PYC do not post here, we do. This is a investment forum after all.

I did like the joined up thinking that you made about Avacta yesterday. Both going to EORTC in Spain at the end of the month.

All very good and like for getting their story out on Linkedin.

However, potential investors probably will not be looking at this for a source of info?

Extract value. That being G-CSF capability that could be lucrative.

Yes.

https://www.physiomics.co.uk/innovate-uk-grant-award/

This is the trial with Beyond Blood and Blackpool for G-CSF ends Oct 2025.

Yes, however, as always with PYC, the proof will be in the contract(s) that can be won, maintained & repeated.

As has been said before, PYC dealt primarily with 1-2 stages of the 4 stages of the development of new drugs. With Biostats, they can now cover all 4 stages.

They obviously have high hopes for the dosing tool, and as some have suggested, that "could" be a company maker. However, that is at least 18months away from i believe getting to its next milestone. Testing on parts will not finish till OCT 2025, then await i would guess 6 months for the data to be sieved through? Maybe Trench/KingLaura or Ralph can clarify?

About The Role:

The successful candidate will join Physiomics’ Quantitative Pharmacology and Data Science consulting team to help us deliver high quality modelling and simulation solutions to our clients. This role is a great opportunity for a motivated individual looking to work on a variety of modelling projects with real impact. They will get the opportunity to both support and lead projects for a range of clients, from emerging to top tier biopharma and research institutes, as well as projects across the drug development phases and across various therapeutic areas. The role offers fantastic career development opportunities, not only through on the job and external training, but provides the opportunity to be involved in the growth of the business, developing new capabilities and expanding teams.

Its a new job. https://www.linkedin.com/jobs/search/?currentJobId=4046673927&keywords=physiomics%20plc&origin=BLENDED_SEARCH_RESULT_NAVIGATION_JOB_CARD&originToLandingJobPostings=4046673927

Thank you Trench.

They did not answer questions on BOD buying shares to show confidence in their company.

Peter could be spreading himself a little thin at the moment, not only as CEO but also heading the Biostats division to.

The 2 "contractors" are Hitesh and Michael. They await a new head to be employeed.

Interesting that again, they use their work with Bicycle to highlight the work on BT 7480. The "heatmap" has been shown before, but not in as much detail as the slide on the website now shows.

Https://www.physiomics.co.uk/solutions/biostatistics/

https://www.physiomics.co.uk/solutions/data-science-and-bioinformatics/

I like this move into Biostatistics. Would be good to know who is running it?